期刊
DRUG DISCOVERY TODAY
卷 20, 期 5, 页码 588-594出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2015.02.013
关键词
-
资金
- Novo Nordisk Foundation [11019]
- Fondo de Investigacion Sanitaria/Instituto de Salud Carlos III [PI13/00090]
- Comunidad de Madrid [S2010/BMD-2312]
- Novo Nordisk Fonden [NNF14OC0011019] Funding Source: researchfish
The development of monoclonal antibody (mAb) technology has had a profound impact on medicine. The therapeutic use of first-generation mAb achieved considerable success in the treatment of major diseases, including cancer, inflammation, autoimmune, cardiovascular, and infectious diseases. Next-generation antibodies have been engineered to further increase potency, improve the safety profile and acquire non-natural properties, and constitute a thriving area of mAb research and development. Currently, a variety of alternative antibody formats with modified architectures have been generated and are moving fast into the clinic. In fact, the bispecific antibody blinatumomab was the first in its class to be approved by the US Food and Drug Administration (FDA) as recently as December 2014. Here, we outline the fundamental strategies used for designing the next generation of therapeutic antibodies, as well as the most relevant results obtained in preclinical studies and clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据